Zhang Yue, Ding Yao, Liao Yiran, Shu Jin, Gong Yi
Phase I Clinical Trial Center, Chongqing University Cancer Hospital, Chongqing, China.
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, China.
Front Pharmacol. 2025 Jul 8;16:1636120. doi: 10.3389/fphar.2025.1636120. eCollection 2025.
Despite significant advances in immune checkpoint inhibitors and targeted therapies, treatment options remain limited for recurrent and metastatic cervical cancer (r/mCC) following progression on first-line therapy. There persists a substantial unmet clinical need for novel therapeutic strategies that are both effective and well-tolerated. In recent years, antibody-drug conjugate (ADC) have gained increasing attention as an emerging form of precision chemotherapy with targeted delivery capabilities, offering a promising therapeutic approach for r/mCC. With the approval of tisotumab vedotin (TV), a tissue factor (TF)-targeting ADC, for the treatment of r/mCC, an increasing number of ADCs targeting different antigens have demonstrated highly encouraging therapeutic potential in cervical cancer patients. The identification of ideal antigenic epitopes represents a critical factor in ADC development. This review outlines promising tumor-associated antigens (TAAs) for ADC targeting in cervical cancer and their biological functions, such as human epidermal growth factor receptor 2 (HER2), trophoblast cell surface antigen 2 (Trop-2), mesothelin, nectin cell adhesion molecule 4 (Nectin-4). We also summarize the clinical applications and research progress of corresponding ADC, and provide novel perspectives for future ADC development and clinical research strategies.
尽管免疫检查点抑制剂和靶向治疗取得了重大进展，但一线治疗进展后的复发性和转移性宫颈癌（r/mCC）的治疗选择仍然有限。对于有效且耐受性良好的新型治疗策略，仍存在大量未满足的临床需求。近年来，抗体药物偶联物（ADC）作为一种具有靶向递送能力的新兴精准化疗形式，越来越受到关注，为r/mCC提供了一种有前景的治疗方法。随着组织因子（TF）靶向ADC替索妥单抗（TV）获批用于治疗r/mCC，越来越多靶向不同抗原的ADC在宫颈癌患者中显示出极具前景的治疗潜力。理想抗原表位的鉴定是ADC开发的关键因素。本综述概述了宫颈癌中用于ADC靶向的有前景的肿瘤相关抗原（TAA）及其生物学功能，如人表皮生长因子受体2（HER2）、滋养层细胞表面抗原2（Trop-2）、间皮素、NECTIN细胞粘附分子4（Nectin-4）。我们还总结了相应ADC的临床应用和研究进展，并为未来ADC的开发和临床研究策略提供了新的视角。
